A carregar...
Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice
Limitations in efficacy and/or tolerance of currently available urate-lowering therapies (ULTs), such as oral xanthine oxidase inhibitors, uricosurics, and intravenous uricase agents contribute to the development of refractory gout. Renal excretion is the major route of uric acid elimination, but th...
Na minha lista:
| Publicado no: | Front Med (Lausanne) |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7732547/ https://ncbi.nlm.nih.gov/pubmed/33330529 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2020.569215 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|